Crossmark

Relationship of nutritional or systemic inflammatory markers with efficacy of gemcitabine and cisplatin with or without durvalumab therapy for patients with unresectable or metastatic biliary tract cancer: a retrospective study

Crossref DOI link: https://doi.org/10.1186/s40780-026-00555-5

Published Online: 2026-02-16

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fukushi, Yayoi

Fujita, Kazuma

Akamine, Yumiko

Igarashi, Haruka

Sasaki, Katsuya

Fukuda, Koji

Shibata, Hiroyuki

Kikuchi, Masafumi
License Information

Text and Data Mining valid from 2026-02-16

Version of Record valid from 2026-03-12
More Information

Article History

Received: 31 August 2025

Accepted: 11 February 2026

First Online: 16 February 2026

Declarations

:

: This study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Review Board of Akita University Graduate School of Medicine (Approval Number: 3067). Informed consent was obtained via opt-out through the website.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below